Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation

Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has entered into a global licensing agreement with LTS Lohmann Therapie-Systeme AG. Headquartered in Andernach, Germany, LTS focuses on creating advanced therapeutic solutions, including transdermal and oral thin film drug delivery technologies in the biotechnology industry. The agreement pertains to an exclusive proprietary S-ketamine formulation, administered sublingually via an oral thin film (OTF). This formulation, successfully evaluated in a Phase 1 clinical trial by LTS, holds global exclusivity for Awakn in its application to addiction, anxiety and eating disorders. LTS has also secured patents in key international markets, including the US, China, Canada, Europe, and Japan. By securing access to the Phase 1 clinical trial data and obtaining exclusive global rights to the proprietary formulation for the specified indications, Awakn ensures robust intellectual property protection and expedites the potential progression to late-stage clinical trials. The sublingual S-ketamine formulation represents a significant advancement in addiction treatment, offering the potential for faster onset of action, precise dosing, and reduced ... Full story available on Benzinga.com ketamine anxiety otc

Read More